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Abstract
Background: In idiopathic pulmonary fibrosis (IPF), fibroblasts gain a more migratory phenotype and excessively
secrete extracellular matrix (ECM), ultimately leading to alveolar scarring and progressive dyspnea. Here, we
analyzed the effects of deficiency of FK506-binding protein 10 (FKBP10), a potential IPF drug target, on primary
human lung fibroblast (phLF) adhesion and migration.
Methods: Using siRNA, FKBP10 expression was inhibited in phLF in absence or presence of 2ng/ml transforming
growth factor-β1 (TGF-β1) and 0.1mM 2-phosphoascorbate. Effects on cell adhesion and migration were monitored
by an immunofluorescence (IF)-based attachment assay, a conventional scratch assay, and single cell tracking by
time-lapse microscopy. Effects on expression of key players in adhesion dynamics and migration were analyzed by
qPCR and Western Blot. Colocalization was evaluated by IF microscopy and by proximity ligation assays.
Results: FKBP10 knockdown significantly attenuated adhesion and migration of phLF. Expression of collagen VI was
decreased, while expression of key components of the focal adhesion complex was mostly upregulated. The effects
on migration were 2-phosphoascorbate-dependent, suggesting collagen synthesis as the underlying mechanism.
FKBP10 colocalized with collagen VI and coating culture dishes with collagen VI, and to a lesser extent with
collagen I, abolished the effect of FKBP10 deficiency on migration.
Conclusions: These findings show, to our knowledge for the first time, that FKBP10 interacts with collagen VI and
that deficiency of FKBP10 reduces phLF migration mainly by downregulation of collagen VI synthesis. The results
strengthen FKBP10 as an important intracellular regulator of ECM remodeling and support the concept of FKBP10
as drug target in IPF.
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Background
Patients suffering from idiopathic pulmonary fibrosis (IPF),
a highly progressive interstitial lung disease, have a median
survival prognosis of 2-5 years after diagnosis [1]. The
pathogenic processes are not completely understood. It is
currently believed that the fibrotic response is caused by re-
peated micro-injuries of the respiratory epithelium [2]
which leads to the release of profibrotic mediators like
transforming growth factor β1 (TGF-β1), followed by myo-
fibroblast differentiation, increased fibroblast migration,
and, ultimately, excessive deposition of extracellular matrix
(ECM) in the alveolar region [3–6]. More recent evidence
suggests that the composition of the ECM strongly affects
fibroblast phenotypes and therefore plays a crucial role in
disease progression [4, 7, 8].
Aberrant fibroblast adhesion and migration are com-
mon features of fibrosis [9–11] and targeting fibroblast
migration, e.g. by inhibition of focal adhesion kinase
(FAK) or of integrins, has been proposed as a treatment
strategy [12, 13]. For instance, myofibroblasts possess an
increased ability to adhere to the ECM, which is
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mediated by focal adhesions (FA) attaching the actin
cytoskeleton to the matrix [14]. Cell attachment to the
ECM via clustering of integrins leads to the recruitment
of numerous FA proteins with adapter, structural, and
enzymatic functions [15, 16]. For instance, structural
proteins like talin, vinculin and α-actinin facilitate the
connection between integrins and actin fibers and pro-
vide the basis for the transmission of mechanical forces
between cell and ECM [17]. To enable cell migration,
turnover of FA is necessary. Several factors are involved
in FA disassembly, like actin dynamics, FAK and Src
phosphorylation, and ERK/MAP kinase-mediated activa-
tion of calpain-2, a calcium-dependent protease [15].
Finally, migration is strongly influenced by topology
and composition of the ECM including integrin ligands
like collagen, fibronectin (FN), and laminin [7]. Collagen
type VI appears to play a particularly important role in
this context, as several studies indicate a central, albeit
context-dependent and tissue-specific role of collagen VI
for migration and adhesion [18–20].
FK506-binding protein 10 (FKBP10, also termed
FKBP65), a member of the family of immunophilins, is
an endoplasmic reticulum (ER) -resident peptidyl prolyl
isomerase and a collagen I chaperone [21]. We have pre-
viously reported upregulation of FKBP10 in experimen-
tal lung fibrosis and IPF, where it is mainly expressed by
(myo)fibroblasts [22]. Deficiency of FKBP10 by siRNA-
mediated knockdown in primary human lung fibroblasts
(phLF) reduced the expression of profibrotic markers
like α-smooth muscle actin (α-SMA), FN and collagen I,
and suppressed collagen secretion [22].
As properties of the ECM play an important role in
adhesion dynamics and FKBP10 has been identified pre-
viously as a regulator of collagen biosynthesis in phLF,
the aim of this study was to assess the effect of FKBP10
deficiency on adhesion and migration in phLF. To
elucidate the underlying mechanisms, we analyzed the
effect of siRNA-mediated knockdown of FKBP10 on
intracellular and membrane-spanning components of
the FA complex, on regulatory events of FA turnover, on
proteins involved in actin dynamics, and, finally, on a se-
lection of ECM proteins with important emerging func-
tions in migration.
Methods
Material
Primers were obtained from MWG Eurofins (Ebersberg,
Germany) and are shown in Table 1. Table 2 contains
used primary antibodies. HRP-linked and fluorescent la-
beled secondary antibodies were purchased from GE
Healthcare Life Sciences (Freiburg, Germany).
Statistical Analysis
Statistical analysis was performed in GraphPadPrism 5
(GraphPad Software, San Diego, CA, USA). Results are
shown as mean ± SEM. Paired t-test was used for statis-
tical analysis. Notably, analysis using a Wilcoxon signed
rank test yielded very similar results except for the
scratch assays shown in Fig. 5a where results just failed
significance (not shown). Significance is indicated as fol-
lows: *p<0.05, **p<0.01, ***p<0.001.
Human Lung Material, Isolation and Culture of phLF
Primary human lung fibroblasts (phLF) were isolated
from human lung tissue and derived from in total eight
different patients. The tissue derived from human lung
explant material of IPF patients or histologically normal
regions adjacent to resected lung tumors was obtained
from the BioArchive CPC-M for lung diseases at the
Comprehensive Pneumology Center (CPC Munich,
Germany). The study was approved by the local ethics
committee of the Ludwig-Maximilians University of
Table 1 Primer table for Real-Time Quantitative Reverse-Transcriptase PCR (qRT-PCR). Primers were synthesized by MWG Eurofins
(Ebersberg, Germany).
Target Species Forward primer (5′-3′) Reverse primer (5′-3′)
CAPNS1 human GACGCTACTCAGATGAAAGT TCTTTGTCAAGAGATTTGAAG
CAV1 human TCACTGTGACGAAATACTG CGTAGATGGAATAGACACG
COL6A1 human GACGCACTCAAAAGCA ATCAGGTACTTATTCTCCTTCA
COL6A2 human AGAAAGGAGAGCCTGCGGAT AGGTCTCCCTCACGTAGGTC
COL6A3 human CTCTACCGAGCCCAGGTGTT ATGAGGGTGCGAACGTACTG
CORO1C human GTTAACAAATGTGAGATTGC TGGAAAAGGTCAGACTTC
DHX8 human TGACCCAGAGAAGTGGGAGA ATCTCAAGGTCCTCATCTTCTTCA
ERK1 human TTCGAACATCAGACCTACT AGGTCCTGCACAATGTAG
FBLN1C human GCCCTGAGAACTACCG GAGAGGTGGTAGTAGGTTATTC
FKBP10 human CGACACCAGCTACAGTAAG TAATCTTCCTTCTCTCTCCA
ITGB1 human TTACAAGGAGCTGAAAAACT AAAATGACTTCTGAGGAAAG
TLN1 human GCTCTTTCTGTCAGATGAT CATAGTGTCCCCATTTC
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Munich, Germany, and all participants gave written in-
formed consent. Isolation and culture of phLF was per-
formed as described previously [22, 23]. Notably, in
previous studies, we have never seen consistent expres-
sion differences between control and IPF fibroblasts, nei-
ther in terms of basal and TGF-β1-induced gene
expression of collagens and collagen biosynthetic en-
zymes, nor in terms of collagen secretion [22, 23].
Transfection of phLF and TGF-β1 Treatment
Cells were seeded at a density of 20.000–25.000 cells/
cm2. Reverse transfection was carried out with human
small interfering RNA of FKBP10 (siRNA) (s34171; Life
Technologies, Carlsbad, CA) or negative control siRNA.
Twenty-four hours later starvation for another 24 hours
in Dulbecco’s modified Eagle medium/F-12 including
0.5% fetal bovine serum and 0.1 mM 2-phospho-L-as-
corbic acid was performed. Then, cells were treated with
2 ng/ml TGF-β1 (R&D Systems, Minneapolis, MN) in
starvation medium for another 24 - 48 h, followed by
harvesting for RNA and protein analysis. Unless stated
otherwise, all data is derived from eight independent
knockdown experiments in at least three and maximally
in eight different human primary fibroblast lines. For
fibroblast lines that had been used for more than one
knockdown experiment in different passages, typically a
mean was formed for these experiments prior to statistical
analysis to avoid overrepresentation of one biological
replicate in the data.
RNA Isolation and Real-Time Quantitative Reverse-
Transcriptase PCR (qRT-PCR) Analysis
RNA isolation and qRT-PCR analysis were performed as
described previously [22, 23].
Protein Isolation and Western Blot analysis
Protein isolation and Western Blot analysis were per-
formed as described previously [22, 23].
Table 2 Primary antibodies used in Western Blot analysis, Immunofluorescence and Proximity Ligation Assays
Target Abbreviation Antibody Provider Application
β-actin ACTB HRP-conjugated anti-ACTB antibody Sigma Aldrich, St. Louis, USA WB
Calpain-4 CAPNS1 mouse monoclonal anti-Calpain-4 Abnova, Taipei City, Taiwan WB, IF, PLA
Caveolin-1 CAV1 rabbit monoclonal anti-Caveolin-1 antibody Cell Signaling, Boston, USA WB
Collagen VI α1 COL6A1 mouse monoclonal anti-Collagen VI A1 antibody Santa Cruz, Dallas, USA WB, IF, PLA
Collagen VI α3 COL6A3 mouse monoclonal anti-Collagen VI A3 antibody Santa Cruz, Dallas, USA IF, PLA
Coronin 1C CORO1C mouse monoclonal anti-CORO1C antibody Santa Cruz, Dallas, USA WB, IF, PLA
Extracellular Signaling Related
Kinase 1
ERK1 mouse monoclonal anti-ERK1 antibody BD Biosciences, New Jersey, USA WB
ER protein 57 (Protein
disulfide-isomerase A3)
ERp57 mouse monoclonal anti-ERp57 Abcam, Cambridge, UK PLA
Fibulin-1 FBLN1 mouse monoclonal anti-FBLN1 antibody Santa Cruz, Dallas, USA WB, IF, PLA
FK506-binding protein 10 FKBP10 rabbit polyclonal anti-FKBP10 antibody ATLAS, Stockholm, Sweden WB, IF, PLA
Focal Adhesion Kinase FAK rabbit polyclonal anti-FAK antibody Santa Cruz, Dallas, USA WB
Golgin97 CDF4 mouse monoclonal anti-Golgin97 antibody Invitrogen, Carlsbad, USA PLA
mouse IgG (neg. ctrl) mouse IgG mouse IgG1κ isotype control eBioscience, San Diego, USA PLA
Integrin-β1 ITGB1 mouse monoclonal anti-ITGB1 antibody Abcam, Cambridge, UK WB
Phosphorylated Extracellular
Signaling Related Kinase 1/2
p-ERK1/2 rabbit monoclonal anti-pERK1/2 (Thr202/Tyr204) Cell Signaling, Boston, USA WB
Phosphorylated Focal
Adhesion Kinase
p-FAK Y397 rabbit monoclonal anti-pFAK (Tyr397) Cell Signaling, Boston, USA WB
Phosphorylated Focal
Adhesion Kinase
p-FAK Y566/577 rabbit monoclonal anti-pFAK (Tyr576/Tyr577) Biomol, Hamburg, Germany WB
Phosphorylated SRC
Proto-Oncogene, Non-
Receptor Tyrosine Kinase
p-Src rabbit polyclonal anti-pSrc (Tyr416) Cell Signaling, Boston, USA WB
SRC Proto-Oncogene, Non-
Receptor Tyrosine Kinase
Src mouse monoclonal anti-Src Cell Signaling, Boston, USA WB
Talin 1 TLN1 mouse monoclonal anti-TLN1 Sigma Aldrich, Dt. Louis, USA WB, IF, PLA
Secondary HRP-linked antibodies and secondary antibodies (Alexa Fluor 488 goat anti-mouse IgG, Alexa Fluor 568 goat anti-rabbit IgG) for IF were purchased from
GE Healthcare Life Sciences (Freiburg, Germany). 4',6-Diamidino-2-phenylindole (DAPI) was used for nuclear staining (Sigma-Aldrich, St. Louis, USA)
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Cell Fixation and Immunofluorescent Stainings
Cells were seeded on FN-coated coverslips (6 μg/mL,
Sigma-Aldrich, St. Louis, USA), followed by serum star-
vation and TGF-β1 treatment for 48h as described
above. The fixation method was chosen accordingly to
the used antibodies. For methanol fixation, cells were
washed once in 1x phosphate-buffered saline (PBS),
followed by fixation with 100% methanol for 2 minutes
on ice and three additional washing steps with 1x PBS to
remove the residual methanol.
For para-formaldehyde (PFA) fixation, cells were
washed once with 1x PBS and 4% PFA was added to the
cells followed by incubation at room temperature for 20
minutes. Residual PFA was removed by three washing
steps with 1x PBS. Staining of the cover slips was per-
formed as described before [22]. Immunofluorescence
(IF) was examined by acquiring z-stack images with an
Axio Imager M2 Microscope (Carl Zeiss, Jena, Germany)
and analysed by AxioVision 4.8 software.
Proximity Ligation Assay (PLA)
Cells were seeded, treated with TGF-β1 for 48h, and
methanol-fixed as described above. The Duolink® PLA Kit
(Sigma Aldrich, St. Louis, USA) was used and carried out
according to the manufacturer’s protocol. Interaction of
FKBP10 with target proteins was visualized using an Axio
Imager M2 Microscope (Carl Zeiss, Jena, Germany).
Cell Adhesion Assay
For analysis of cell attachment in FKBP10-deficient
phLF, cells were seeded and treated as described above.
After 48h of TGF-β1 treatment and 96h of siRNA
knockdown, cells were trypsinized and counted. Per con-
dition, four replicates with 100.000 cells per 48-well
were seeded and incubated for 1 hour at 37°C, 5% CO2.
Wells were carefully washed once with 1 x PBS to re-
move non-adherent cells and attached cells were fixed
with 4% PFA as described before. Cells were stained with
4′,6-Diamidin-2-phenylindol (DAPI) and Phalloidin, la-
beled with Alexa Fluor 568 (Invitrogen) followed by im-
aging using an LSM T-PMT microscope (Carl Zeiss,
Jena, Germany). Attached cells were counted using
IMARIS Software 9.0. Results were normalized to non-
treated control and visualized as percentage of attached
cells.
Scratch Assay
Cells were seeded at a density of 35.000 cells/cm2 and
siRNA-mediated knockdown of FKBP10 was performed
as described above. To reach 100% confluency, cells
were grown for 48h followed by starvation for 24h. A
scratch was executed using a 1000 μL pipette tip and
TGF-β1 was added. Images were taken at time point 0h
using an inverse microscope (Primovert, Carl Zeiss, Jena,
Germany) and the section was marked by a black dot.
After 24h, additional images were taken to compare
wound closure between control and FKBP10 deficient
cells. Results are given in percent of wound closure nor-
malized to untreated control.
Single Cell Migration Assay Using Time Lapse Microscopy
Cells were seeded at a density of 5.500 cells/cm2 on
uncoated, collagen I-coated (~50 μg/mL, Sigma-Aldrich,
St. Louis, USA), or collagen VI-coated (10 μg/mL,
Abcam, Cambridge, UK) wells. Knockdown by siRNA of
FKBP10 was performed as described above. After 24h,
cells were serum-starved for another 24h followed by
TGF-β1 treatment (2 ng/mL) for 24h. Movies were gen-
erated over a period of 12h - 24h using Axio Observer
Z1 microscope equipped with an AxioCam camera (Carl
Zeiss, Jena, Germany) and images were taken in 20 min
intervals. Single cell movement was analyzed using the
cell tracking tool of the AxioVision 4.8 software (Carl
Zeiss, Jena, Germany).
Results
Deficiency of FKBP10 attenuates migration and adhesion
of primary human lung fibroblasts
SiRNA-mediated knockdown of FKBP10 expression in
phLF was highly efficient on both protein and mRNA
level (Fig. 1a, b, knockdown efficiency 86% ± 5%).
Wound closure in a conventional scratch assay was sig-
nificantly reduced in FKBP10-deficient cells compared
to control in absence of TGF-β1. A similar trend was
observed in presence of TGF-β1, which just failed sig-
nificance (Fig. 1c, d). These results were confirmed with
an independent and more accurate method, namely a
single cell migration assay using time-lapse microscopy
to track individual cells. In this assay, FKBP10-deficient
cells showed a highly significant reduction of mean vel-
ocity both in absence and presence of TGF-β1 (Fig. 1e).
Next, we investigated the effect of siRNA-mediated
knockdown of FKBP10 on adhesion of phLF using an
IF-based attachment assay. In presence of TGF-β1,
FKBP10 deficiency significantly reduced the ability of
phLF to adhere to the cell culture dish surface (Fig. 1f ).
While TGF-β1 had no significant effect on migration,
neither in the scratch nor in the single cell tracking
assay, TGF-β1 significantly increased fibroblast adhesion.
Deficiency of FKBP10 upregulates expression of key
molecules of adhesion and migration in primary human
lung fibroblasts, but does not alter the activation of focal
adhesion kinase and downstream pathways
To gain a better understanding of the effect of FKBP10
deficiency on adhesion and migration, we analyzed sev-
eral selected proteins with key functions in these pro-
cesses. In terms of altered gene expression of focal
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adhesion and ECM components, we only observed mar-
ginal differences between fibroblasts isolated from nor-
mal histology control or from IPF lung tissue and
therefore decided to pool the data. Deficiency of FKBP10
in phLF led to induction of the focal adhesion compo-
nent talin-1 (TLN1) on protein and mRNA level in ab-
sence and presence of TGF- β1 (Fig. 2a, b). Next, we
investigated the effect of FKBP10 knockdown on
calpain-4 (CAPNS1), the small regulatory subunit of
calpain-1 and calpain-2, which is indispensable for for-
mation and strengthening of adhesions and for mechan-
osensing during fibroblast migration [24]. Similar to
TLN1, CAPNS1 expression was significantly upregulated
in absence and presence of TGF-β1 on transcript level
(Fig. 2c, d); this effect, however, translated to the protein
level only in absence of TGF-β1. Moreover, FKBP10
a b
c d
e f
Fig. 1 Knockdown of FKBP10 reduces migration and adhesion of phLF. a Western Blot analysis of phLF treated with scrambled siRNA as control
(sc) or FKBP10 siRNA (kd) and 2-phosphoascorbate (0.1 mM) in absence and presence of TGF-β1 (2 ng/mL) for 48h. Densitometric analysis and
representative blots show the effect of FKBP10 knockdown on the expression of FKBP10 relative to β-actin as loading control (ACTB). b Quantitative
reverse transcriptase-polymerase chain reaction analysis of phLF treated with sc siRNA as control or FKBP10 siRNA (kd) and 2- phosphoascorbate
(0.1 mM) in absence and presence of TGF-β1 (2 ng/mL) for 48h. Transcript levels are shown as -ΔCt values. DEAH (Asp-Glu-Ala-His) Box
Polypeptide 8 (DHX8) was used as endogenous control. Data (a, b) is based on eight independent experiments. c Representative images
of a scratch assay of phLF treated with sc siRNA as control or FKBP10 and 2- phosphoascorbate (0.1 mM) in absence or presence of TGF-
β1 (2 ng/mL). Images were taken at 0h and after 24h. d Analysis of open wound areas as shown in (c) normalized to controls at 0h
(100%), given in % of the remaining wound area. Data is based on four independent experiments. e SCM assay of phLF treated with sc
siRNA as control or FKBP10 siRNA and 2- phosphoascorbate (0.1 mM) in absence and presence of TGF-β1 (2 ng/mL). Cells were tracked
over a period of 12h - 24h. Results of five independent experiments are shown as mean velocity of around 80 tracked cells per condition.
f Cell attachment assay of phLF treated with sc siRNA as control or FKBP10 siRNA in absence or presence of TGF-β1 (2 ng/mL) for 48h.
Results originate from six independent experiments and are visualized as percentage of cell adhesion normalized to non TGF-β1-
treated cells. Statistical significance between control and FKBP10 kd is indicated by horizontal brackets and asterisks
Knüppel et al. Respiratory Research  (2018) 19:67 Page 5 of 14
knockdown also increased protein levels of the trans-
membrane collagen receptor integrin-β1 (ITGB1), par-
ticularly in presence of TGF-β1 (Fig. 2e), while
transcript levels were not significantly changed (Fig. 2f ).
Finally, two modulators of cytoskeleton dynamics,
caveolin-1 (CAV1) and coronin-1C (CORO1C), were
regulated in opposite directions: Whereas CAV1 expres-
sion (protein and mRNA) was downregulated upon
FKBP10 knockdown in presence of TGF-β1 (Fig. 2g, h),
CORO1C protein levels were upregulated (Fig. 2i, j).
FAK activation by either integrins or growth factors
leads to autophosphorylation of Tyr 397 in FAK,
creating a motif which results in binding and conform-
ational activation of proto-oncogene tyrosine-protein
kinase Src. Active Src triggers further FAK phosphor-
ylation on Tyr sites like Tyr 576/577, starting the ras-
raf-MEK-ERK signal transduction cascade which is
implicated in many processes including cell adhesion
and migration. MEK1/2 catalyzes ERK1/2 phosphoryl-
ation on specific Tyr and Thr residues essential for
enzyme activity [25, 26].
Deficiency of FKBP10 slightly upregulated total FAK
levels (Fig. 3a); however, there was no significant effect
on the phosphorylation on Tyr 397 or Tyr 576/577 of
a
b
c
d
g
h j
i
e
f
Fig. 2 FKBP10 deficiency alters the expression of molecules implicated in adhesion and migration. a, c, e, g, i Western Blot analysis of phLF
treated with scrambled siRNA as control (sc) or FKBP10 siRNA (kd) and 2- phosphoascorbate (0.1 mM) in absence and presence of TGF-β1 (2 ng/mL)
for 48h. Densitometric analysis and representative blots show the effect of FKBP10 kd on the expression of talin-1 (TLN1) (a), calpain-4 (CAPNS1) (c),
integrin β1 (ITGB1) (e), caveolin-1 (CAV1) (g) and coronin 1C (CORO1C) (i) relative to β-actin as loading control (ACTB). b, d, f, h, j Quantitative reverse
transcriptase-polymerase chain reaction analysis of phLF treated with scrambled siRNA as control (sc) or FKBP10 siRNA (kd) and 2- phosphoascorbate
(0.1 mM) in absence and presence of TGF-β1 (2 ng/mL) for 48h. Transcript levels are presented as -ΔCt values showing the effect of siRNA mediated
kd of FKBP10 on talin-1 (TLN1) (b), calpain-4 (CAPNS1) (d), integrin β1 (ITGB1) (f), caveolin-1 (CAV1) (h) and coronin 1C (CORO1C) (j). DEAH (Asp-Glu-
Ala-His) Box Polypeptide 8 (DHX8) was used as endogenous control. All data is based on eight (protein) or seven (mRNA) independent experiments.
Statistical significance between control and FKBP10 kd is indicated by horizontal brackets and asterisks
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FAK (Fig. 3b, c). Similarly, none of the assessed down-
stream signaling pathways appeared affected: Neither
levels of total Src and phospho-Src nor levels of total
ERK1 and phosphorylated ERK1/2 changed upon
FKBP10 knockdown (Fig. 3d-g).
FKBP10 interacts with type VI collagen and fibulin-1 and
regulates their expression
As changes in expression of focal adhesion complex
components and in events during FAK signaling did not
explain the observed attenuated migration upon FKBP10
knockdown, we reasoned that changes in ECM compos-
ition could be the main cause of reduced migration vel-
ocity. Besides the ECM proteins collagen I and FN,
which we reported to be downregulated upon FKBP10
knockdown previously [22], collagen VI and fibulin-1
also have been described to maintain important roles in
the process of cell migration [18, 27]. Here, we found
that collagen VI and fibulin-1 expression were regulated
in different directions in response to FKBP10 knock-
down. Collagen 6A1 was significantly reduced on protein
level in FKBP10 deficient phLF with and without TGF-
β1, whereas COL6A1 transcript was only reduced in
presence of TGF-β1 (Fig. 4a, b). Interestingly, mRNA
levels of COL6A2 and COL6A3 chains were not influ-
enced by FKBP10 deficiency (Fig. 4c, d). In contrast,
fibulin-1 protein expression was increased in response to
FKBP10 knockdown in absence and presence of TGF-
β1; transcript levels of FBLN1C were significantly upreg-
ulated under basal conditions upon FKBP10 knockdown
(Fig. 4e, f ).
Co-localization of FKBP10 with both, collagen VI
(COL6A1 and COL6A3) (Fig. 4g, h) and fibulin-1 (Fig. 4i)
was examined by IF stainings and PLA (Fig. 4j). Negative
a
b
c
d
e
f
g
Fig. 3 Neither FAK, Src, nor ERK1/2 activation is affected by FKBP10 kd. Western Blot analysis of phLF treated with scrambled siRNA as control (sc)
or FKBP10 siRNA (kd) and 2- phosphoascorbate (0.1 mM) in absence and presence of TGF-β1 (2 ng/mL) for 48h. Densitometric analysis and representative
blots show the effect of FKBP10 kd on the expression of FAK (a), Src (d) and ERK1 (f) relative to β-actin as loading control (ACTB). b, c Densitometric analysis
and representative blots showing the effect of FKBP10 kd on the phosphorylation of FAK (Y397) (b) and FAK (Y576/577) (c) relative to FAK. e, g
Densitometric analysis and representative blots showing the effect of FKBP10 kd on the phosphorylation of Src (Y416) (e) relative to Src
and pERK1/2 (T202/Y204) (g) relative to ERK1. All data is based on eight independent experiments. Statistical significance between control
and FKBP10 kd is indicated by horizontal brackets and asterisks
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a b c
d e f
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Fig. 4 FKBP10 interacts with COL6A1 and FBLN1 and regulates their expression. a, e Western Blot analysis of phLF treated with scrambled siRNA
as control (sc) or FKBP10 siRNA (kd) and 2- phosphoascorbate (0.1 mM) in absence and presence of TGF-β1 (2 ng/mL) for 48h. Densitometric analysis
and representative blots showing the effect of FKBP10 kd on the expression of Collagen VI alpha1 (COL6A1) (a) and fibulin-1 (FBLN1) (e) relative to β-
actin as loading control (ACTB). b, c, d, f Quantitative reverse transcriptase-polymerase chain reaction analysis of phLF treated with sc siRNA as control
or FKBP10 siRNA and 2-phosphoascorbate (0.1 mM) in absence and presence of TGF-β1 (2 ng/mL) for 48h. Transcript levels are shown as -ΔCt values
of showing the effect of FKBP10 kd on collagen VI alpha 1 (COL6A1) (b), collagen VI alpha 2 (COL6A2) (c), collagen VI alpha 3 (COL6A3) (d) and
fibulin-1C (FBLN1C) (f). DEAH (Asp-Glu-Ala-His) Box Polypeptide 8 (DHX8) was used as endogenous control. All data is based on eight (protein)
or seven (mRNA) independent experiments. Statistical significance is indicated by horizontal brackets and asterisks. g-i Immunofluorescence staining of
FKBP10 (green) and COL6A1 (red) (g), COL6A3 (red) (h) and FBLN1 (red) (i). 4`, 6-diamidino-2-phenylindole (DAPI) staining is shown in blue. The region
of interest is indicated by a white square and enlarged in the picture below. White arrows specify examples for co-localization of FKBP10 with COL6A1,
COL6A3 or FBLN1. Stainings were taken as z-stack and the enlarged pictures show one focal plane from this z-stack. Representative images were
selected from three independent experiments. j Representative images of in situ localization of the interaction of FKBP10 and COL6A1,
COL6A3, FBLN1, mouse IgG1κ (negative control), Golgin97 (negative control) and ERp57 (positive control), assessed by proximity ligation
assay. Representative images were selected from three independent experiments, except for IgG negative control (n=1)
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controls (mouse IgG and Golgin97) did not show any
interaction with FKBP10. Endoplasmic Reticulum Protein
57 (ERp57), previously reported by IF to co-localize with
FKBP10 [22] was used as positive control and showed
proximity to FKBP10. Positive signals were also observed
for COL6A1, COL6A3 and FBLN1, indicating interaction
with or proximity to FKBP10.
The effects of FKBP10 deficiency on migration and
adhesion depend on 2-phosphoascorbate and are
abolished by coating cell culture dishes with collagen VI
Post-translational modifications (PTM) like proline and
lysine hydroxylation of collagens (including collagen VI)
are crucial steps in collagen biosynthesis and catalyzed
by ascorbate-dependent prolyl and lysyl hydroxylases
[28–30]. In contrast, FBLN1 biosynthesis is not
dependent on ascorbate [31]. Therefore, we reasoned
that exclusion of ascorbate from the culture medium
would give us a first indication whether decreased
biosynthesis of collagen or increased biosynthesis of
fibulin may underlie the observed effects of FKBP10
deficiency on migration and adhesion. Notably, in ab-
sence of 2-phosphoascorbate the effect of FKBP10 de-
ficiency in phLF on adhesion and migration was lost,
in comparison to the results in presence of 2-
phosphoascorbate (Fig. 5), pointing towards a
collagen-dependent mechanism.
As both collagen I and collagen VI are downregulated
upon FKBP10 deficiency [22], we coated dishes with ei-
ther collagen I or collagen VI and analyzed migration in
a single-cell migration approach. Notably, the effect of
FKBP10 deficiency in phLFs on migration was com-
pletely lost when culture dishes were coated with
collagen VI (Fig. 6b) when compared to uncoated dishes
a
b
Fig. 5 The inhibitory effect of FKBP10 deficiency on migration and adhesion is 2-phosphoascorbate dependent. a Analysis of open wound areas
in scratch assays of phLF treated with scrambled siRNA (sc) as control or FKBP10 siRNA (kd) in absence and presence of TGF-β1 (2 ng/mL) and 0.1
mM 2-phosphoascorbate. Images were taken at 0h and after 24h. Data is normalized to controls at 0h (100%), given in % of the remaining wound
area and based on four independent experiments. b Cell attachment assay of phLF treated with scrambled siRNA (sc) as control or FKBP10 siRNA
(kd) in absence or presence of TGF-β1 (2 ng/mL) and 2-phosphoascorbate (0.1 mM) for 48h. Results originate from six independent experiments
and are visualized as percentage of cell adhesion normalized to non TGF-β1 treated. Experiments without and with 2- phosphoascorbate were
performed in parallel
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(Fig. 6a). Some compensation was also visible in collagen
I-coated dishes, albeit not that pronounced (Fig. 6c).
Discussion
In this study we demonstrated that FKBP10 deficiency
inhibited phLF adhesion and migration. This effect could
neither be explained by changes in expression or activa-
tion of components of the FA complex, nor by changes
in FAK downstream signaling events, nor by changes in
regulators of actin dynamics. Instead, we found that the
effect of FKBP10 deficiency on migration and adhesion
depended on 2-phosphoascorbate, pointing towards a
central role of collagen biosynthesis in this context. Loss
of FKBP10 downregulated the expression of collagen VI,
a collagen type increasingly recognized as a central
player in migration, and coating culture dishes with col-
lagen VI completely abolished the effect of FKBP10 defi-
ciency on phLF migration.
Next to excessive ECM deposition by interstitial fibro-
blasts, aberrant fibroblast adhesion and increased migra-
tion are also important features of IPF [6, 9–11]. Here
we show that loss of the collagen chaperone FKBP10,
which we previously identified as potential IPF drug tar-
get due to its role in ECM synthesis and secretion [22],
inhibited wound closure and reduced the mean velocity
and adhesion capacity of phLF (Fig. 1). This observation
is in line with the very recent report by Liang et al.,
showing that siRNA-mediated knockdown of FKBP10
led to reduced migration in human hypertrophic scar fi-
broblasts [32]. Collectively, these studies are confirma-
tive of our concept of FKBP10 as potential drug target in
fibrotic disease.
We assessed fibroblast migration both in a conven-
tional scratch assay as well as by tracking individual cells
with videomicroscopy in time-lapse experiments, a more
accurate approach. Overall, both assays consistently
showed reduced migration under conditions of FKBP10
deficiency, even if the scratch assay results in presence
of TGF-β1 failed significance (p=0.06). We believe that
this minor discrepancy reflects the well-known disadvan-
tages of the scratch assay, most importantly variations in
gap width due to the manually applied and therefore
often uneven scratch, the fact that ECM substrate is
equally scraped off together with the cells, and also the
mechanical cell damage which may introduce artifacts.
These technical drawbacks may explain the greater vari-
ations observed in this assay, leading to results that just
fail significance.
Our finding that TGF-β1 did not affect fibroblast mi-
gration is in agreement with previous studies by others
[33–35]. Increased fibroblast adhesion in presence of
TGF-β1 may in part reflect increased expression of β1-
integrin (this work, cf. Fig. 2e, f, scr ctrl vs. scr TGF-β1,
p=0.0642) and/or β3-integrins [36].
Initially, we sought to assess the effect of FKBP10 defi-
ciency on several regulatory levels of FA turnover to elu-
cidate the mechanism underlying attenuated migration.
Cell migration is a complex cyclic process starting with
the extension of membrane protusions (lamellipodia) at
the leading edge followed by their adhesion to the ECM
and retraction of the cell tail [37]. During cell migration
assembly and disassembly of FA is dynamically regu-
lated. The process of cell attachment to the ECM is initi-
ated by clustering of integrins on the cell surface,
heterodimeric transmembrane receptors consisting of α
and β subunits. The intracellular domains of the clus-
tered integrins serve as a platform for FA protein re-
cruitment and ultimately link the ECM via FA to actin
stress fibers [38]. In this context, TLN1 mediates the ini-
tiation of FA assembly by interacting with the cytoplas-
mic domain of the integrin β subunit on the one hand
and with actin and actin-binding proteins on the other
[15]. Another initial event upon integrin clustering is ac-
tivation of FAK including autophosphorylation of Tyr
a b c
Fig. 6 Coating of dishes with collagen VI abolishes the inhibitory effect of FKBP10 knockdown on migration. SCM assay of phLF treated with
scrambled siRNA as control (sc) or FKBP10 siRNA (kd) and 2- phosphoascorbate (0.1 mM) in absence and presence of TGF-β1 (2 ng/mL). Cells
were tracked over a period of 12h -24h. Results of three independent experiments are shown as mean velocity of around 80 tracked cells per
condition. Effect of collagen VI coated dishes on mean velocity of phLF is shown in (b) and of collagen I coated dishes in (c) compared to
uncoated dishes for control (a). Statistical significance between control and FKBP10 kd is indicated by horizontal brackets and asterisks
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397 and Src-mediated phosphorylation of additional
tyrosine residues within FAK (e.g. Y 566 and 577), which
are essential for full FAK activity. Active FAK interacts
with multiple signalling molecules including Grb7, PI3K,
paxillin, MLCK and ERK, activating signalling pathways
which result in protrusion extension, increased FA turn-
over, and therefore, ultimately, in increased cell motility
[15, 39–42]. The protease calpain 2, a heterodimer con-
sisting of a catalytic subunit and a regulatory subunit
(calpain-4, CAPNS1) plays a central role in this context
as it, when recruited by FAK and activated by ERK/MAP
kinase, mediates amongst others proteolysis of TLN1
and FAK, considered the rate-limiting step in FA turn-
over [15, 38, 39, 43, 44]. Finally, directional cell migra-
tion is strongly dependent on polarized actin dynamics.
Rho-like GTPases like RhoA and Rac1 control cytoskel-
eton contractility, polymerization, and protrusion. The
integral membrane protein caveolin-1 (Cav-1), activated
by small kinases like Src, is a central regulator of Rho-
like GTPase signaling in this context [45, 46]. Another
regulator of actin filament turnover in the lamellipodia
during cell migration is the actin binding protein coro-
nin 1C (CORO1C) [47].
FKBP10 deficiency led to several significant changes in
expression of FA components on all levels assessed, i.e.
upregulation of ITGB1, TLN1, CAPNS1, FAK, CORO1C
and downregulation of CAV1 (Fig. 2). Upregulation of
ITGB1 may associate with reduced FA turnover and
slow migration [48–50] but impaired migration and ad-
hesion has also been reported as a result of ITGB1 defi-
ciency [51]. Collectively, these findings suggest that
manipulation of ITGB1 protein levels in general is un-
favorable to cell motility, regardless of direction of regu-
lation. As ITGB1 functions as an adapter protein
between the ECM and intracellular FA complexes, it is
conceivable that its expression levels must be tightly reg-
ulated to allow for functional intermolecular interactions
between different interacting partners.
The same may apply to TLN1, an adapter protein link-
ing the cytoskeleton to ITGB1, where reports in the lit-
erature are also seemingly controversial: Upregulation of
TLN1, but also suppression of TLN1 has been reported
to reduce migration and adhesion [52–54]. Interestingly,
downregulation of TLN1 has also been associated with
increased migration [52, 55], which is in support of its
function as a regulator of FA turnover together with its
protease calpain-2 [15, 38, 39, 43, 44]. In our system,
however, the simultaneous increase of the regulatory cal-
pain 2 subunit CAPNS1, argues for overall little change
in FA turnover, at least in absence of TGF-β1 (Fig. 2c,
d). This is consistent with our observation that phos-
phorylation levels of FAK, Src, and ERK (Fig. 3), central
signaling events in the process of FA turnover [39, 56–58]
remained unchanged.
At first, observing inhibition of adhesion and migra-
tion in the absence of changes in activation of FAK and
related signaling pathways seemed contradictory to us.
However, similarly, Asano and colleagues have reported
that siRNA-mediated knockdown of α-smooth muscle
actin (α-SMA) in phLF led to inhibition of migration
without affecting the FAK signaling pathway [59]. This
observation suggested that changes in actin dynamics
may underlie the observed inhibition of migration and,
indeed, from our previous studies, we know that FKBP10
deficiency reduces α-SMA expression in phLF [22]. Also,
deficiency of the actin binding protein CORO1C typic-
ally results in inhibition of migration; however, here, we
observed a moderate increase of CORO1C protein ra-
ther than downregulation (Fig. 2i) [60, 61]. Expression of
CAV1, deficiency of which typically results in decreased
migratory speed in variable cell types [62–64], was only
moderately downregulated in presence of TGF-β1
(Fig. 2g, h). Collectively, these observations do not
argue for altered actin dynamics as a major mechan-
ism underlying inhibition of migration in response to
FKBP10 deficiency.
Importantly, cell migration is influenced by properties
of the ECM, like density of adhesion ligands (collagen,
FN), ECM composition, and stiffness [7, 65]. Previously,
we have observed downregulation of expression and se-
cretion of type I collagen and FN, both major compo-
nents of the fibroblast ECM, in response to FKBP10
knockdown [22]. Here we extended this analysis and
assessed additional ECM components with important
roles in cell migration, namely type VI collagen and
FBLN1. Both proteins colocalized with FKBP10 in phLF,
as assessed by both immunofluorescence colocalization
analysis and proximity ligation assay (Fig. 4g-j), indicat-
ing direct interaction with FKBP10 in the ER. Interest-
ingly, we found that loss of FKBP10 significantly
increased FBLN1 expression (Fig. 4e, f ), but decreased
protein levels of COL6A1 (Fig. 4a, b). Notably, COL6A1
deficiency is sufficient to inhibit collagen VI deposition
in the ECM, as no triple helical molecules can be formed
without the α1(VI)-chain [66]. These results suggest op-
posing functions of FKBP10 in FBLN1 and collagen VI
biosynthesis in phLF. It is tempting to speculate, for in-
stance, that FKBP10 acts as a FBLN1 chaperone, seques-
tering FBLN1 in the ER, prohibiting packing in vesicles
for secretion or targeting FBLN1 for ER-associated pro-
tein degradation, while at the same time FKBP10 is likely
required for efficient collagen VI triple helix formation,
similar to collagen I and III [21, 67, 68]. These aspects
will be interesting to explore in future studies.
As to function of these proteins in migration, reduced
attachment and decreased migratory speed has been re-
ported for a human breast cancer cell line (MDA
MB231) in response to FBLN1 overexpression [27] and
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siRNA mediated knockdown of FBLN1 in corneal fibro-
blasts upregulated cell migration [69]. Therefore, taken
together, it was plausible that increased FBLN1 levels
may underlie the observed inhibition of migration under
conditions of FKBP10 deficiency.
While collagen VI begins to emerge as an important
regulator of cell migration, reports on its direction of ef-
fect, inhibiting or promoting migration, are controversial
[18–20]. For instance, collagen VI-deficient tendon fi-
broblasts show delayed wound closure, i.e. lower migra-
tion speed, in a scratch assay [18], while human dermal
fibroblasts displayed higher migration speed on matrices
derived from collagen VI-deficient cells [20]. These dis-
crepancies may be a result of the divergent approaches
in the mentioned studies (assessment of newly formed
ECM versus assessment of ECM deposited within 10
days, respectively), different collagen VI chains assessed
(COL6A1 versus COL6A2), but also of the different cell
origins, thus possibly reflecting time-, chain-, and cell-
specific effects of collagen VI.
Ascorbic acid is a cofactor necessary for proline and
lysine hydroxylation during collagen synthesis [68] in-
cluding collagen VI [30, 70], but not required for FBLN1
synthesis. Therefore, to differentiate between increased
FBLN1 or decreased type VI collagen as the underlying
mechanism of decreased adhesion and migration, we
compared effects of FKBP10 knockdown on adhesion
and migration in absence and presence of 2-
phosphoascorbate, a stable analogue of ascorbic acid.
Notably, neither migration nor adhesion were changed
upon loss of FKBP10 when the cell culture medium was
ascorbate-deficient (Fig. 5a, b). These results strongly in-
dicated that the effect of FKBP10 deficiency on adhesion
and migration was collagen-dependent. While coating
with collagen VI abolished the effect of FKBP10 knock-
down on migration completely, coating with collagen I
only did so marginally (Fig. 6). Overall, this indicated
that FKBP10 knockdown inhibits lung fibroblast migra-
tion by reduced collagen VI biosynthesis rather than
reduced collagen I biosynthesis, an effect of FKBP10
deficiency which we have reported previously [22].
Conclusion
Collagen VI is an important regulator of the ECM or-
ganizing the three-dimensional meshwork of collagen
and FN fibers [71, 72] and the topography of the fibrillar
ECM network guides directional cell migration [73].
Therefore, our observations suggest that loss of FKBP10
results in reduced biosynthesis of collagen VI and, pos-
sibly in combination with decreased extracellular colla-
gen I levels, leads to a disorganized ECM with changed
adhesion ligand density, stiffness and composition,
which may not provide sites for integrin clustering and
does not favor directional cell migration. Upregulation
of ITGB1, TLN1, CAPNS1, total FAK, and CORO1C
may ultimately reflect an attempt of the cells to over-
come decreased migration by overcompensation, in-
creasing expression of ECM receptors or components of
the FA turnover machinery.
Interestingly, FKBP10 mediates dimerization with col-
lagen lysyl hydroxylase 2 and thus contributes to the
generation of collagen hydroxylysines, which act as sub-
strates for extracellular lysyl-oxidase-mediated collagen
crosslinking [74–76]. Extracellular collagen lacking
proper crosslinks is prone to proteolytic degradation and
may not be able to contribute to the higher ordered
organization of the ECM anymore [77–80]. Therefore,
downregulation of FKBP10 may also contribute to
disorganization of the ECM by providing less crosslink-
ing sites in type I and type VI collagen.
In summary, we found that loss of FKBP10 in phLF re-
sults in decreased adhesion and migration. We found
that the main underlying mechanism was reduced colla-
gen VI biosynthesis, as both ascorbate deficiency and
coating of cell culture dishes with collagen VI abolished
the effect of FKBP10 knockdown on migration. As in-
creased fibroblast migration is a characteristic of IPF, the
results are in support of our concept of FKBP10 as a po-
tential drug target for IPF.
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